vic3308

º²É­ÖÆÒ© º²É­ÖÆÒ©

ά¶àÀûÑÇÀÏÆ·ÅÆvic3308(Öйú)¹É·ÝÓÐÏÞ¹«Ë¾ ¼ò ¤™
  • ¼ò
  • ·±
  • EN
¤œ
Ïà¹ØÁ´½Ó
  • vic3308¥Y
ά¶àÀûÑÇÀÏÆ·ÅÆvic3308(Öйú)¹É·ÝÓÐÏÞ¹«Ë¾
ÐÂÎÅÐû²¼
Press Release
Ê×Ò³  >  ÐÂÎÅÖÐÐÄ  >  ÐÂÎÅÐû²¼
JCTH I È«ÇòÊ׸öÕë¶ÔALTÕý³£ÂýÒÒ¸ÎÈËȺRCT£¬ £¬£¬£¬£¬ºããå?PROMOTE 48ÖÜЧ¹û½ÒÏþ
Ðû²¼ÈÕÆÚ£º2025/07/04
×ÖºÅ

- PROMOTEÑо¿ÊÇÈ«ÇòÊ׸öÕë¶ÔALTˮƽÕý³£µÄÂýÐÔHBVѬȾÕßµÄÇ°Õ°ÐÔ¡¢¶àÖÐÐÄ¡¢Ëæ»ú±ÈÕÕÑо¿£¬ £¬£¬£¬£¬ÎªALTÕý³£µÄÂýÐÔHBVѬȾÈËȺÊÇ·ñÐèÒª¿¹²¡¶¾ÖÎÁÆÌṩÁËÑϽ÷µÄ¿Æѧ֤¾Ý¡£¡£¡£¡£¡£¡£¡£¡£

- ±¾´ÎJCTH½ÒÏþµÄPROMOTEÑо¿48ÖÜЧ¹ûÅú×¢£ººããå?ÔÚÖÎÁÆALTÕý³£µÄÂýÐÔHBVѬȾÕßÖÐÈ¡µÃÁËÏÔÖøÁÆЧ£¬ £¬£¬£¬£¬ÇÒ¾ßÓÐÓÅÒìµÄ¹Ç÷À¡¢ÉöÔàºÍѪ֬Çå¾²ÐÔ[1]¡£¡£¡£¡£¡£¡£¡£¡£

- PROMOTEÑо¿Îª½üÄêÀ´¸Î²¡Ñ§½çÌᳫµÄÂýÐÔÒҸΡ°À©´óÖÎÁÆ¡±ÉõÖÁ¡°È«ÖΡ±£¨Treat All£©Õ½ÂÔÌṩÁËÖ÷ÒªµÄÁÙ´²Ö¤¾ÝÖ§³Ö£¬ £¬£¬£¬£¬¹ØÓÚ¼õÇáÉç»á¼°»¼Õß¼²²¡¼ç¸ºÓÐ×ÅÖ÷ÒªÒâÒå¡£¡£¡£¡£¡£¡£¡£¡£


¿ËÈÕ£¬ £¬£¬£¬£¬¸Î²¡ÁìÓòȨÍþÔÓÖ¾¡¶ÁÙ´²Óëת»¯¸ÎÔಡѧÔÓÖ¾¡·£¨Journal of Clinical and Translational Hepatology£©½ÒÏþÁËÒ»ÏîÆÀ¹Àº²É­ÖÆÒ©×ÔÖ÷Ñз¢µÄÖйúÊ׸öÔ­Ñпڷþ¿¹ÒÒÐ͸ÎÑײ¡¶¾Ò©Îïºããå?µÄPROMOTEÑо¿48ÖÜÆÊÎöЧ¹û¡£¡£¡£¡£¡£¡£¡£¡£

Ñо¿Ð§¹ûÅú×¢£¬ £¬£¬£¬£¬×ÝÈ»¹ØÓÚALTÕý³£µÄÂýÐÔÒҸλ¼Õߣ¬ £¬£¬£¬£¬½ÓÄÉÓÐÓõĿ¹²¡¶¾ÖÎÁÆ£¨Èçºããå?£©Ò²ÄÜÏÔÖøÒÖÖƲ¡¶¾¸´ÖÆ£¬ £¬£¬£¬£¬¸ÄÉƸÎÔàÑ×Ö¢±ê¼ÇÎ½µµÍALTˮƽ¼°¡°Õý³£¸ßÖµ¡±ALT±ÈÀý£©£¬ £¬£¬£¬£¬²¢¿ÉÄܽµµÍ¼²²¡Ï£ÍûΣº¦£¬ £¬£¬£¬£¬Í¬Ê±¾ßÓÐÓÅÒìµÄ¹Ç÷À¡¢ÉöÔàºÍѪ֬Çå¾²ÐÔ¡£¡£¡£¡£¡£¡£¡£¡£

¹Å°å¿´·¨ÒÔΪ£¬ £¬£¬£¬£¬µ±ÂýÒҸλ¼Õß·ºÆðALTÉý¸ßʱ£¬ £¬£¬£¬£¬²ÅÌáÐѸÎÔàÑ×Ö¢Ô˶¯²¢Æô¶¯¿¹²¡¶¾ÖÎÁÆ¡£¡£¡£¡£¡£¡£¡£¡£È»¶øÔ½À´Ô½¶àÖ¤¾ÝÅú×¢£¬ £¬£¬£¬£¬ÔÚÂýÒҸλ¼ÕßȺÌåÖУ¬ £¬£¬£¬£¬ALTˮƽÕý³£µÄ»¼ÕßÒ²¿ÉÄܱ£´æÏÔÖøµÄ¸ÎÔಡÀí¸Ä±ä£¬ £¬£¬£¬£¬°üÀ¨¸ÎÏËά»¯ÉõÖÁ¸Îϸ°û°©£¨HCC£©Î£º¦¡£¡£¡£¡£¡£¡£¡£¡£Õë¶ÔÕâÒ»Ö÷Òªµ«³£±»ºöÊÓµÄÈËȺ£¬ £¬£¬£¬£¬PROMOTEÑо¿ÆÀ¹ÀÁ˺ããå?ÔÚALTÕý³£ÂýÐÔÒҸλ¼ÕßÖеÄÁÆЧÓëÇå¾²ÐÔ¡£¡£¡£¡£¡£¡£¡£¡£

Ñо¿¼ò½é


PROMOTEÑо¿£¨NCT05797714£©ÊÇÊ׸öÕë¶ÔALTˮƽÕý³££¨ALT£¼40 IU/L£©µÄÂýÐÔHBVѬȾÕßµÄÇ°Õ°ÐÔ¡¢¶àÖÐÐÄ¡¢Ëæ»ú¡¢¿ª·Å±êÇ©¡¢¿Õȱ±ÈÕÕÁÙ´²ÊÔÑ飬 £¬£¬£¬£¬¹²ÓÐ12¼ÒҽѧÖÐÐļÓÈë¡£¡£¡£¡£¡£¡£¡£¡£

Èë×黼ÕßËæ»ú·ÖΪÁ½×飺ÖÎÁÆ×飨n=95£©¿Ú·þTMF 25mg£¬ £¬£¬£¬£¬ÖðÈÕÒ»´Î£¬ £¬£¬£¬£¬¼ÆÆëÕûÁ¬ÖÎÁÆ144ÖÜ£»£»£»£»£»£»£»±ÈÕÕ×飨n=102£©²»½ÓÊÜ¿¹²¡¶¾ÖÎÁÆ£¬ £¬£¬£¬£¬½öËæ·ÃÊÓ²ìÖÁ144ÖÜ¡£¡£¡£¡£¡£¡£¡£¡£PROMOTEÑо¿48ÖÜЧ¹ûÏÔʾ£º

¡ñ TMFÏÔÖøÒÖÖƲ¡¶¾¸´ÖÆ

ÔÚÖ÷ÒªÖÕµãÆÊÎöÖУ¨FAS¼¯£©£¬ £¬£¬£¬£¬TMF×é48ÖÜʱµÖ´ïÍêÈ«²¡¶¾Ñ§Ó¦´ð£¨HBV DNA < 20 IU/mL£©µÄ»¼Õß±ÈÀý¸ß´ï74.2%£¬ £¬£¬£¬£¬¶ø±ÈÕÕ×é½öΪ9.0%£¨P < 0.001£©¡£¡£¡£¡£¡£¡£¡£¡£×ÝÈ»ÔÚδµÖ´ïÍêÈ«²¡¶¾Ñ§Ó¦´ðµÄTMF×黼ÕßÖУ¬ £¬£¬£¬£¬´ó´ó¶¼»¼Õß²¡¶¾ÔØÁ¿½µÖÁ20-2000 IU/mLµÄµÍˮƽ¡£¡£¡£¡£¡£¡£¡£¡£¶ø±ÈÕÕ×éÓÐÁè¼ÝÒ»°ë£¨53%£©µÄ»¼ÕßHBV DNA > 2000 IU/mL¡£¡£¡£¡£¡£¡£¡£¡£

±ðµÄ£¬ £¬£¬£¬£¬TMF×éÊӲ쵽1ÀýHBsAgÏûÊż°ÑªÇåѧת»»²¡Àý£¬ £¬£¬£¬£¬±ÈÕÕ×éδÊӲ쵽´ËÀàѪÇåѧ¸ÄÉÆ¡£¡£¡£¡£¡£¡£¡£¡£HBsAgˮƽÔÚTMF×éµÄ½µ·ùÒ²ÏÔÖø´óÓÚ±ÈÕÕ×飨-0.07 vs -0.04 log10 IU/mL£¬ £¬£¬£¬£¬P=0.02£©¡£¡£¡£¡£¡£¡£¡£¡£

¡ñ TMF¸ÄÉƸÎÔàÑ×֢״̬

TMF×黼ÕßµÄALTˮƽ×ÔÖÎÁƺóÓÐËùϽµ£¬ £¬£¬£¬£¬²¢ÔÚ48ÖÜÄÚÒ»Á¬Î¬³ÖÔڽϵÍˮƽ¡£¡£¡£¡£¡£¡£¡£¡£Ïà±È±ÈÕÕ×飬 £¬£¬£¬£¬TMF×éALT½Ï»ùÏߵİٷֱȽµ·ùÏÔÖø¸ü´ó£¨-14.09%vs0%£¬ £¬£¬£¬£¬ P=0.003£©¡£¡£¡£¡£¡£¡£¡£¡£TMFÖÎÁÆ»¹ÏÔÖø½µµÍÁËALT¡°Õý³£¸ßÖµ¡±£¨20-40 IU/L£©µÄ»¼Õß±ÈÀý£¨´Ó»ùÏß60.9%½µÖÁ48ÖÜ46.2%£©£¬ £¬£¬£¬£¬Ê¹¸ü¶à»¼ÕßµÄALTˮƽ½µÖÁ¸üÇå¾²µÄ¡°µÍÕý³£¡±¹æÄ££¨¡Ü20 IU/L£©¡£¡£¡£¡£¡£¡£¡£¡£

Ïà±È֮ϣ¬ £¬£¬£¬£¬±ÈÕÕ×éÓÐ7Àý»¼Õߣ¨7.0%£©·ºÆðÁËÇкϼ²²¡Ï£Íû±ê×¼µÄALTÖèÉý£¨ALT Flare£¬ £¬£¬£¬£¬½ç˵ΪALT > 2¡ÁULN£©£¬ £¬£¬£¬£¬¶ø²»µÃ²»ÌáǰתÓÃTMFÖÎÁÆ£¬ £¬£¬£¬£¬Í¹ÏÔÁËδÖÎÁÆ»¼ÕßDZÔڵļ²²¡Ô˶¯Î£º¦£¨P=0.014£©¡£¡£¡£¡£¡£¡£¡£¡£TMF×éÔòÎÞ´ËÀàÊÂÎñ±¬·¢¡£¡£¡£¡£¡£¡£¡£¡£

¡ñ ¹ÇÉöÇå¾²ÐÔÓÅÒ죬 £¬£¬£¬£¬ÇÒ¶ÔѪ֬ÎÞ²»Á¼Ó°Ïì

Çå¾²ÐÔ·½Ã棬 £¬£¬£¬£¬TMF×éÓë±ÈÕÕ×éÔÚ48ÖÜʱµÄѪ¼¡ôû¡¢¹ÀËãÉöСÇòÂ˹ýÂÊ£¨eGFR£©¡¢ÑªÇåÁ×ÒÔ¼°¹Çת»»±ê¼ÇÎ¦Â-CTx, P1NP£©µÄת±ä¾ùÎÞÏÔÖø²î±ð£¨ËùÓÐP > 0.05£©£¬ £¬£¬£¬£¬ÌáÐÑTMFµÄÉöÔà/¹Ç÷ÀÇå¾²ÐÔÓÅÒì¡£¡£¡£¡£¡£¡£¡£¡£TMF×éµÄ×ܵ¨¹Ì´¼¡¢¸ÊÓÍÈýõ¥¡¢µÍÃܶÈÖ¬ÂÑ°×£¨LDL£©¡¢¸ßÃܶÈÖ¬ÂÑ°×£¨HDL£©µÈÖ¸±êµÄת±äÓë±ÈÕÕ×éÏà±ÈÒàÎÞÏÔÖø²î±ð£¨ËùÓÐP > 0.05£©£¬ £¬£¬£¬£¬ÌáÐÑTMF¶ÔѪ֬Æ×ÎÞ²»Á¼Ó°Ïì¡£¡£¡£¡£¡£¡£¡£¡£

TMF×ÜÌåÄÍÊÜÐÔÓÅÒì¡£¡£¡£¡£¡£¡£¡£¡£´ó´ó¶¼ÖÎÁÆÖзºÆðµÄ²»Á¼ÊÂÎñ£¨TEAE£©ÎªÇá¶È¡£¡£¡£¡£¡£¡£¡£¡£TMF×é¡Ý3¼¶TEAE±¬·¢ÂʽöΪ2.1%£¬ £¬£¬£¬£¬½ö1Àý»¼ÕßÒò²»Á¼ÊÂÎñÍ£Ò©¡£¡£¡£¡£¡£¡£¡£¡£ÎÞéæÃü²¡Àý±¨¸æ¡£¡£¡£¡£¡£¡£¡£¡£

Ñо¿Õß»¹½«½øÒ»²½Íƽø¹ØÓÚºããå?96ÖܺÍ144Öܵĺã¾ÃÁÆЧ£¨°üÀ¨HBsAgϽµ¡¢HBeAgѪÇåѧת»»£©¡¢ºã¾ÃÇå¾²ÐÔÒÔ¼°HBeAgÑôÐÔ»¼ÕßÒ»Á¬ÖÎÁÆ»ñÒæµÄÑо¿ÊӲ죬 £¬£¬£¬£¬ÕâЩЧ¹û¹ØÓÚÓÅ»¯ÂýÐÔÒÒ¸ÎÖÎÀíÕ½ÂÔ£¬ £¬£¬£¬£¬ÌØÊâÊÇÃ÷È·ALTÕý·²ÈËȺµÄÖÎÁƼÛÖµºÍʱ»ú£¬ £¬£¬£¬£¬¾ßÓÐÖ÷ÒªÒâÒå¡£¡£¡£¡£¡£¡£¡£¡£

²Î¿¼ÎÄÏ×£º

[1]Gui H, Shen Y, Tan L, Hu P, Qian F, Wu X, et al. Interim Analysis of 48-week Tenofovir Amibufenamide Treatment in Chronic Hepatitis B Patients with Normal Alanine Aminotransferase Levels: The PROMOTE Study. J Clin Transl Hepatol. Published online: Jun 30, 2025. doi: 10.14218/JCTH.2025.00162.

¹ØÓÚº²É­ÖÆÒ©

º²É­ÖÆÒ©ÊÇÖйúÁìÏȵÄÁ¢ÒìÇý¶¯ÐÍÖÆÒ©ÆóÒµ£¬ £¬£¬£¬£¬ÒÔ¡¸Ò»Á¬Á¢Ò죬 £¬£¬£¬£¬Ìá¸ßÈËÀàÉúÃüÖÊÁ¿¡¹ÎªÊ¹Ãü£¬ £¬£¬£¬£¬Öصã¹Ø×¢¿¹Ö×Áö¡¢¿¹Ñ¬È¾¡¢ÖÐÊàÉñ¾­ÏµÍ³¡¢´úл¼°×ÔÉíÃâÒßµÈÖØ´ó¼²²¡ÖÎÁÆÁìÓò¡£¡£¡£¡£¡£¡£¡£¡£×èÖ¹ÏÖÔÚ£¬ £¬£¬£¬£¬¹«Ë¾ÒÑÉÏÊÐ7¿îÁ¢ÒìÒ©£¬ £¬£¬£¬£¬ÐγÉÁ×Æ»ºñµÄ²úÆ·¹ÜÏß¡£¡£¡£¡£¡£¡£¡£¡£º²É­ÖÆÒ©Ò»Á¬¶àÄêλ¾ÓÈ«ÇòÖÆÒ©ÆóÒµ°ÙÇ¿¡¢ÖйúÒ½Ò©Ñз¢²úÆ·Ïß×î¼Ñ¹¤ÒµÆóҵǰ3Ç¿£¬ £¬£¬£¬£¬Êǹú¼ÒÖصã¸ßÐÂÊÖÒÕÆóÒµ¡¢¹ú¼ÒÊÖÒÕÁ¢ÒìÊ÷Ä£ÆóÒµ¡£¡£¡£¡£¡£¡£¡£¡£º²É­ÖÆÒ©ÓÚ2019Äê6ÔÂÔÚÏã¸ÛÁª½»Ëù¹ÒÅÆÉÏÊУ¨¹ÉƱ´úÂ룺03692.HK£©¡£¡£¡£¡£¡£¡£¡£¡£¸ü¶àÐÅÏ¢Çë»á¼û£º/¡£¡£¡£¡£¡£¡£¡£¡£

ÃâÔðÉùÃ÷

±¾ÎĽö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ£¬ £¬£¬£¬£¬·Ç¹ã¸æÓÃ;¡£¡£¡£¡£¡£¡£¡£¡£º²É­ÖÆÒ©²»ÍƼöÈκÎδ»ñÅúҩƷʹÓúÍ/»òδ»ñÅú˳Ӧ֢ÓÃÒ©£¬ £¬£¬£¬£¬Òà²î³ØÈκÎÒ©Æ·ºÍ/»ò˳Ӧ֢×÷ÍƼö¡£¡£¡£¡£¡£¡£¡£¡£±¾Í¨¸æÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼£¬ £¬£¬£¬£¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£¡£¡£¡£¡£¡£¡£¡£Ò½ÁÆÎÀÉúרҵÈËÊ¿×÷³öµÄÈκÎÓëÖÎÁÆÓйصľöÒéӦƾ֤»¼ÕßµÄÏêϸÇéÐβ¢×ñÕÕҩƷ˵Ã÷Êé¡£¡£¡£¡£¡£¡£¡£¡£ÈçÐèÏàʶ¹«Ë¾ÈκβúÆ·¡¢Ò½ÁÆ»ò¼²²¡µÄÏà¹ØÐÅÏ¢£¬ £¬£¬£¬£¬ÇëÎñ±Ø×ÉѯҽÁÆÎÀÉúרҵÈËÊ¿¡£¡£¡£¡£¡£¡£¡£¡£

Ç°Õ°ÐÔ˵Ã÷

±¾ÐÂΟåÖ¼ÔÚÌṩ¹ØÓÚº²É­ÖÆÒ©¼¯ÍÅÓÐÏÞ¹«Ë¾¼°ÆäÁ¥Êô¹«Ë¾£¨°üÀ¨Æä×Ó¹«Ë¾£¬ £¬£¬£¬£¬Í³³ÆΪ¡°º²É­ÖÆÒ©¡±£©µÄÐÅÏ¢¡£¡£¡£¡£¡£¡£¡£¡£Ëü²»×é³É¶Ôº²É­ÖÆÒ©»òÈκÎͶ×ʽ¨ÒéµÄÐÅÏ¢Åû¶¡£¡£¡£¡£¡£¡£¡£¡£

±¾ÐÂΟå°üÀ¨µÄÐÅÏ¢¿ÉÄÜ°üÀ¨Ó뺲ɭÖÆÒ©ÓªÒµºÍ²úÆ·Ô¶¾°¡¢ÍýÏë¡¢ÐÅÐÄ¡¢Ô¤ÆÚºÍÕ½ÂÔÏà¹ØµÄÇ°Õ°ÐÔÉùÃ÷¡£¡£¡£¡£¡£¡£¡£¡£ÕâЩÉùÃ÷ÊÇ»ùÓÚÍƲâÐÔ¼ÙÉèµÄÕ¹Íû£¬ £¬£¬£¬£¬²¢²»°ü¹ÜδÀ´µÄÌåÏÖ¡£¡£¡£¡£¡£¡£¡£¡£ËüÃÇÊܵ½ÖîÈç¿Æѧ¡¢ÉÌÒµ¡¢ÕþÖΡ¢¾­¼Ã¡¢²ÆÎñ¡¢Ö´·¨ÒòËØÒÔ¼°¾ºÕùÇéÐκÍÉç»áÌõ¼þµÈΣº¦ºÍ²»È·¶¨ÐÔµÄÓ°Ï죬 £¬£¬£¬£¬ÕâЩÒòËØÐí¶à¶¼ÊǺ²É­ÖÆÒ©ÎÞ·¨¿ØÖÆÇÒÄÑÒÔÕ¹ÍûµÄ£¬ £¬£¬£¬£¬Òò´ËÏÖʵЧ¹û¿ÉÄÜÓë´ËµØ·½ÊöÓÐÏÔÖø²î±ð£¬ £¬£¬£¬£¬ÇÒÒÑÍùµÄ֤ȯ¼ÛÇ®Ç÷ÊƲ»Ó¦×÷ΪδÀ´ÐÐÇéµÄÖ¸µ¼¡£¡£¡£¡£¡£¡£¡£¡£Òò´Ë£¬ £¬£¬£¬£¬Í¶×ÊÕßÔÚʹÓÃÕâЩÐÅÏ¢¾ÙÐÐͶ×ʾöÒéʱӦÉóÉ÷ÐÐÊ¡£¡£¡£¡£¡£¡£¡£¡£¡°ÖÂÁ¦ÓÚ¡±¡°Ô¤ÆÚ¡±¡°ÐÅÍС±¡°Õ¹Íû¡±¡°Òâͼ¡±¡°Ô¤¼Æ¡±¡°¿ÉÄÜ¡±¡°½«¡±¡°Ó¦¸Ã¡±¡°ÍýÏ롱¡°¼ÌÐø¡±¡°Ä¿µÄ¡±¡°Ë¼Á¿¡±¡°Ô¤¼Æ¡±¡°Ö¸µ¼¡±¡°Ç±ÔÚ¡±¡°×·Çó¡±ÒÔ¼°ÓÚÈκÎδÀ´ÍýÏë¡¢Ðж¯»òÊÂÎñµÄÌÖÂÛÖÐʹÓõÄÀàËÆ´ÊÓïºÍÊõÓ £¬£¬£¬£¬¾ùÌåÏÖÇ°Õ°ÐÔÉùÃ÷¡£¡£¡£¡£¡£¡£¡£¡£

º²É­ÖÆÒ©²»ÔÊÐí»ò°ü¹ÜÇ°Õ°ÐÔÐÅÏ¢µÄ׼ȷÐÔ¡¢ÊµÊ±ÐÔ»òÍêÕûÐÔ£¬ £¬£¬£¬£¬²¢ÇÒ²»¼ç¸º¸üлòÐÞ¶©ÕâЩǰհÐÔÉùÃ÷µÄÒåÎñ¡£¡£¡£¡£¡£¡£¡£¡£ÎÞÂÛÊǺ²É­ÖÆÒ©ÕÕ¾ÉÆäÈκζ­Ê¡¢Ô±¹¤»òÊðÀíÈË£¬ £¬£¬£¬£¬¾ù²î³ØÈκÎ֤ʵ½û¾øÈ·»òÎÞ·¨ÊµÏÖµÄÇ°Õ°ÐÔÉùÃ÷ÈÏÕ棬 £¬£¬£¬£¬Ò²²î³ØÒòÒÀÀµ±¾ÐÂΟåÖÐÌṩµÄÐÅÏ¢¶ø±¬·¢µÄÈκÎËðʧ»òËðº¦ÈÏÕ棬 £¬£¬£¬£¬°üÀ¨µ«²»ÏÞÓÚÖ±½Ó¡¢ÎÞÒâ¡¢¼ä½Ó»ò´¦·ÖÐÔµÄË𺦡£¡£¡£¡£¡£¡£¡£¡£

ά¶àÀûÑÇÀÏÆ·ÅÆvic3308(Öйú)¹É·ÝÓÐÏÞ¹«Ë¾
¡¾ÍøÕ¾µØͼ¡¿¡¾sitemap¡¿